Association between the brief inventory of neurocognitive impairment (BINI) and objective cognitive testing among persons with opioid use disorders in drug treatment

References

• Anand P, Springer SA, Copenhaver MM, Altice FL. Neurocognitive impairment and HIV risk factors: a reciprocal relationship. AIDS Behav. 2010;14(6):1213–26. doi:10.1007/s10461-010-9684-1.
   PubMed Web of Science ®Google Scholar
• Baldacchino A, Balfour DJK, Passetti F, Humphris G, Matthews K. Neuropsychological consequences of chronic opioid use: A quantitative review and meta-analysis. Neurosci Biobehav Rev. 2012;36(9):2056–68. doi:10.1016/j.neubiorev.2012.06.006.
   PubMed Web of Science ®Google Scholar
• Rapeli P, Kivisaari R, Autti T, Kahkonen S, Puuskari V, Jokela O, Kalska H. Cognitive function during early abstinence from opioid dependence: a comparison to age, gender, and verbal intelligence matched controls. BMC Psychiatry. 2006;6(1):9. http://www.biomedcentral.com/1471-244X/6/9 doi:10.1186/1471-244X-6-9.
   PubMed Web of Science ®Google Scholar
• Schiltenwolf M, Akbar M, Hug A, Pfüller U, Gantz S, Neubauer E, Flor H, Wang H. Evidence of specific cognitive deficits in patients with chronic low back pain under long-term substitution treatment of opioids. Pain Physician. 2014;17(1):9–20.
   PubMed Web of Science ®Google Scholar
• Verdejo-García A, López-Torrecillas F, Giménez C, Pérez-García M. Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse. Neuropsychol Rev. 2004;14(1):1–41. doi:10.1023/B:NERV.0000026647.71528.83.
   PubMed Web of Science ®Google Scholar
• Loeber S, Duka T, Welzel H, Nakovics H, Heinz A, Flor H, Mann K. Impairment of cognitive abilities and decision making after chronic use of alcohol: the impact of multiple detoxifications. Alcohol Alcohol. 2009;44(4):372–81.
   PubMed Web of Science ®Google Scholar
• Nordahl TE, Salo R, Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatry Clin Neurosci. 2003;15(3):317–25. doi:10.1176/jnp.15.3.317.
   PubMed Web of Science ®Google Scholar
• Norman LR, Basso M, Kumar A, Malow R. Neuropsychological consequences of HIV and substance abuse: a literature review and implications for treatment and future research. Curr Drug Abuse Rev. 2009;2(2):143–56. Retrieved from http://www.ingentaconnect.com/content/ben/cdar/2009/00000002/00000002/art00005 doi:10.2174/1874473710902020143.
   PubMedGoogle Scholar
• Shrestha R, Huedo-Medina TB, Copenhaver MM. Sex-related differences in self-reported neurocognitive impairment among high-risk cocaine users in methadone maintenance treatment program. Subst Abuse: Res Treat. 2015;9:17–24. doi:10.4137/SART.S23332.
   PubMed Web of Science ®Google Scholar
• Solfrizzi V, D’Introno A, Colacicco AM, Capurso C, Del Parigi A, Baldassarre G, Scapicchio P, Scafato E, Amodio M, Capurso A, Italian Longitudinal Study on Aging Working Group, et al. Alcohol consumption, mild cognitive impairment, and progression to dementia. Neurology. 2007;68(21):1790–9. doi:10.1212/01.wnl.0000262035.87304.89.
   PubMed Web of Science ®Google Scholar
• Spronk DB, van Wel JHP, Ramaekers JG, Verkes RJ. Characterizing the cognitive effects of cocaine: a comprehensive review. Neurosci Biobehav Rev. 2013;37(8):1838–59. doi:10.1016/j.neubiorev.2013.07.003.
   PubMed Web of Science ®Google Scholar
• Stampfer MJ, Kang JH, Chen J, Cherry R, Grodstein F. Effects of moderate alcohol consumption on cognitive function in women. N Engl J Med. 2005;352(3):245–53. doi:10.1056/NEJMoa041152.
   PubMed Web of Science ®Google Scholar
• Vonmoos M, Hulka LM, Preller KH, Minder F, Baumgartner MR, Quednow BB. Cognitive impairment in cocaine users is drug-induced but partially reversible: evidence from a longitudinal study. Neuropsychopharmacology. 2014;39(9):2200–10. doi:10.1038/npp.2014.71.
   PubMed Web of Science ®Google Scholar
• Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87. doi:10.1016/S0140-6736(10)60829-X.
   PubMed Web of Science ®Google Scholar
• Kamarulzaman A, Altice FL. Challenges in managing HIV in people who use drugs. Curr Opin Infect Dis. 2015;28(1):10–6. doi:10.1097/QCO.0000000000000125.
   PubMed Web of Science ®Google Scholar
• Bates ME, Pawlak AP, Tonigan JS, Buckman JF. Cognitive impairment influences drinking outcome by altering therapeutic mechanisms of change. Psychol Addict Behav. 2006;20(3):241–53. doi:10.1037/0893-164X.20.3.241.
   PubMed Web of Science ®Google Scholar
• Blume AW, Davis JM, Schmaling KB. Neurocognitive dysfunction in dually-diagnosed patients: a potential roadblock to motivating behavior change. J Psychoact Drugs. 1999;31(2):111–5. doi:10.1080/02791072.1999.10471732.
   PubMed Web of Science ®Google Scholar
• Huedo-Medina TB, Shrestha R, Copenhaver M. Modeling a theory-based approach to examine the influence of neurocognitive impairment on HIV risk reduction behaviors among drug users in treatment. AIDS Behav. 2016;20(8):1646–57. doi:10.1007/s10461-016-1394-x.
   PubMed Web of Science ®Google Scholar
• Morgenstern J, Bates ME. Effects of executive function impairment on change processes and substance use outcomes in 12-step treatment. J Stud Alcohol. 1999;60(6):846–55. doi:10.15288/jsa.1999.60.846.
   PubMed Web of Science ®Google Scholar
• Nakagami E, Hoe M, Brekke JS. The prospective relationships among intrinsic motivation, neurocognition, and psychosocial functioning in schizophrenia. Schizophr Bull. 2010;36(5):935–48. doi:10.1093/schbul/sbq043.
   PubMed Web of Science ®Google Scholar
• Ezeabogu I, Copenhaver MM, Potrepka J. The influence of neurocognitive impairment on HIV treatment outcomes among drug-involved people living with HIV/AIDS. AIDS Care. 2012;24(3):386–93. doi:10.1080/09540121.2011.608794.
   PubMed Web of Science ®Google Scholar
• Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9. doi:10.1111/j.1532-5415.2005.53221.x.
   PubMed Web of Science ®Google Scholar
• Ridley N, Batchelor J, Draper B, Demirkol A, Lintzeris N, Withall A. Cognitive screening in substance users: diagnostic accuracies of the mini-mental state examination, addenbrooke's cognitive examination-revised, and montreal cognitive assessment. J Clin Exp Neuropsychol. 2018;40(2):107–22. doi:10.1080/13803395.2017.1316970.
   PubMed Web of Science ®Google Scholar
• Alarcon R, Nalpas B, Pelletier S, Perney P. MoCA as a screening tool of neuropsychological deficits in alcohol-dependent patients. Alcohol Clin Exp Res. 2015;39(6):1042–8. doi:10.1111/acer.12734.
   PubMed Web of Science ®Google Scholar
• Copersino ML, Fals-Stewart W, Fitzmaurice G, Schretlen DJ, Sokoloff J, Weiss RD. Rapid cognitive screening of patients with substance use disorders. Exp Clin Psychopharmacol. 2009;17(5):337–44. doi:10.1037/a0017260.
   PubMed Web of Science ®Google Scholar
• Copersino ML, Schretlen DJ, Fitzmaurice GM, Lukas SE, Faberman J, Sokoloff J, Weiss RD. Effects of cognitive impairment on substance abuse treatment attendance: predictive validation of a brief cognitive screening measure. Am J Drug Alcohol Abuse. 2012;38(3):246–50. doi:10.3109/00952990.2012.670866.
   PubMed Web of Science ®Google Scholar
• Hagen E, Sømhovd M, Hesse M, Arnevik EA, Erga AH. Measuring cognitive impairment in young adults with polysubstance use disorder with MoCA or BRIEF-A - The significance of psychiatric symptoms. J Subst Abuse Treat. 2019;97:21–7. doi:10.1016/j.jsat.2018.11.010.
   PubMed Web of Science ®Google Scholar
• Boustani M, Peterson B, Hanson L, Harris R, Lohr KN. Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2003;138(11):927–37. doi:10.7326/0003-4819-138-11-200306030-00015.
   PubMed Web of Science ®Google Scholar
• Khachaturian ZS, Camí J, Andrieu S, Avila J, Boada Rovira M, Breteler M, Froelich L, Gauthier S, Gómez-Isla T, Khachaturian AS, et al. Creating a transatlantic research enterprise for preventing Alzheimer's disease. Alzheimers Dement. 2009;5(4):361–6. doi:10.1016/j.jalz.2009.05.158.
   PubMedGoogle Scholar
• Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol. 1982;21(1):1–16. doi:10.1111/j.2044-8260.1982.tb01421.x.
   PubMed Web of Science ®Google Scholar
• McNair D, Kahn R. Self-assessment of cognitive deficits. In: Crook T, Ferris S, Bartus R, editors. Assessment in geriatric psychopharmacology. New Canaan, Conn.: Mark Powley Associates; 1983. p. 137–43.
   Google Scholar
• Smith G, Della Sala S, Logie RH, Maylor EA. Prospective and retrospective memory in normal ageing and dementia: a questionnaire study. Memory. 2000;8(5):311–21. doi:10.1080/09658210050117735.
   PubMed Web of Science ®Google Scholar
• Rabin LA, Smart CM, Crane PK, Amariglio RE, Berman LM, Boada M, Buckley RF, Chételat G, Dubois B, Ellis KA, et al. Subjective cognitive decline in older adults: an overview of self-report measures used across 19 international research studies. J Alzheimers Dis. 2015;48 Suppl 1(01):S63–S86. doi:10.3233/jad-150154.
   PubMedGoogle Scholar
• Jessen F, Feyen L, Freymann K, Tepest R, Maier W, Heun R, Schild H-H, Scheef L. Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiol Aging. 2006;27(12):1751–6. doi:10.1016/j.neurobiolaging.2005.10.010.
   PubMed Web of Science ®Google Scholar
• Mosconi L, De Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik-Sobanska L, Rich KE, Switalski R, Mehta PD, Pratico D, et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry. 2008;63(6):609–18. doi:10.1016/j.biopsych.2007.05.030.
   PubMed Web of Science ®Google Scholar
• Perrotin A, Mormino EC, Madison CM, Hayenga AO, Jagust WJ. Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol. 2012;69(2):223–9. doi:10.1001/archneurol.2011.666.
   PubMedGoogle Scholar
• Zlatar ZZ, Moore RC, Palmer BW, Thompson WK, Jeste DV. Cognitive complaints correlate with depression rather than concurrent objective cognitive impairment in the successful aging evaluation baseline sample. J Geriatr Psychiatry Neurol. 2014;27(3):181–7. doi:10.1177/0891988714524628.
   PubMed Web of Science ®Google Scholar
• Zlatar ZZ, Muniz M, Galasko D, Salmon DP. Subjective cognitive decline correlates with depression symptoms and not with concurrent objective cognition in a clinic-based sample of older adults. J Gerontol B Psychol Sci Soc Sci. 2018;73(7):1198–202. doi:10.1093/geronb/gbw207.
   PubMed Web of Science ®Google Scholar
• Le Berre A-P, Sullivan EV. Anosognosia for memory impairment in addiction: insights from neuroimaging and neuropsychological assessment of metamemory. Neuropsychol Rev. 2016;26(4):420–31. doi:10.1007/s11065-016-9323-3.
   PubMed Web of Science ®Google Scholar
• Copenhaver M, Shrestha R, Wickersham JA, Weikum D, Altice FL. An exploratory factor analysis of a brief self-report scale to detect neurocognitive impairment among participants enrolled in methadone maintenance therapy. J Subst Abuse Treat. 2016;63:61–5. doi:10.1016/j.jsat.2016.01.002.
   PubMed Web of Science ®Google Scholar
• Heaton RK, Franklin DR, Deutsch R, Letendre S, Ellis RJ, Casaletto K, Marquine MJ, Woods SP, Vaida F, Atkinson JH, for the CHARTER Group, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis. 2015;60(3):473–80. doi:10.1093/cid/ciu862.
   PubMed Web of Science ®Google Scholar
• Jak AJ, Preis SR, Beiser AS, Seshadri S, Wolf PA, Bondi MW, Au R. Neuropsychological criteria for mild cognitive impairment and dementia risk in the framingham heart study. J Int Neuropsychol Soc. 2016;22(9):937–43. doi:10.1017/S1355617716000199.
   PubMed Web of Science ®Google Scholar
• Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385–401. doi:10.1177/014662167700100306.
   Web of Science ®Google Scholar
• Buckley R, Saling MM, Ames D, Rowe CC, Lautenschlager NT, Macaulay SL, Martins RN, Masters CL, O'Meara T, Savage G, Australian Imaging Biomarkers and Lifestyle Study of Aging (AIBL) Research Group, et al. Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age. Int Psychogeriatr. 2013;25(8):1307–15. doi:10.1017/s1041610213000665.
   PubMed Web of Science ®Google Scholar
• Galioto R, Blum AS, Tremont G. Subjective cognitive complaints versus objective neuropsychological performance in older adults with epilepsy. Epilepsy Behav. 2015;51:48–52. doi:10.1016/j.yebeh.2015.06.035.
   PubMed Web of Science ®Google Scholar
• Saloner R, Grelotti DJ, Tyree G, Sundermann EE, Ma Q, Letendre S, Heaton RK, Cherner M. Benzodiazepine use is associated with an increased risk of neurocognitive impairment in people living with HIV. J Acquir Immune Defic Syndr. 2019;82(5):475–82. doi:10.1097/qai.0000000000002183.
   PubMed Web of Science ®Google Scholar
• Mizuno A, Ly M, Aizenstein HJ. A homeostatic model of subjective cognitive decline. Brain Sci. 2018;8(12):228. doi:10.3390/brainsci8120228.
   PubMed Web of Science ®Google Scholar
• Si T, Xing G, Han Y. Subjective cognitive decline and related cognitive deficits. Front Neurol. 2020;11:247. doi:10.3389/fneur.2020.00247.
   PubMed Web of Science ®Google Scholar
• Avants SK, Margolin A, McMahon TJ, Kosten TR. Association between self-report of cognitive impairment, HIV status, and cocaine use in a sample of cocaine-dependent methadone-maintained patients. Addict Behav. 1997;22(5):599–611. doi:10.1016/S0306-4603(96)00070-6.
   PubMed Web of Science ®Google Scholar
• Copenhaver M, Avants SK, Warburton LA, Margolin A. Intervening effectively with drug abusers infected with HIV: taking into account the potential for cognitive impairment. J Psychoact Drugs. 2003;35(2):209–18. doi:10.1080/02791072.2003.10400002.
   PubMed Web of Science ®Google Scholar
• Gunstad J, Cohen RA, Paul RH, Tate DF, Hoth KF, Poppas A. Understanding reported cognitive dysfunction in older adults with cardiovascular disease. Neuropsychiatr Dis Treat. 2006;2(2):213–8. doi:10.2147/nedt.2006.2.2.213.
   PubMedGoogle Scholar
• Darke S, Sims J, McDonald S, Wickes W. Cognitive impairment among methadone maintenance patients. Addiction. 2000;95(5):687–95. doi:10.1046/j.1360-0443.2000.9556874.x.
   PubMed Web of Science ®Google Scholar
• Loeber S, Kniest A, Diehl A, Mann K, Croissant B. Neuropsychological functioning of opiate-dependent patients: a nonrandomized comparison of patients preferring either buprenorphine or methadone maintenance treatment. Am J Drug Alcohol Abuse. 2008;34(5):584–93. doi:10.1080/00952990802308239.
   PubMed Web of Science ®Google Scholar
• Mintzer MZ, Stitzer ML. Cognitive impairment in methadone maintenance patients. Drug Alcohol Depend. 2002;67(1):41–51. doi:10.1016/S0376-8716(02)00013-3.
   PubMed Web of Science ®Google Scholar
• Rapeli P, Fabritius C, Alho H, Salaspuro M, Wahlbeck K, Kalska H. Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clin Pharmacol. 2007;7:5. doi:10.1186/1472-6904-7-5.
   PubMedGoogle Scholar
• Verdejo A, Toribio I, Orozco C, Puente KL, Perez-Garcia M. Neuropsychological functioning in methadone maintenance patients versus abstinent heroin abusers. Drug Alcohol Depend. 2005;78(3):283–8. doi:10.1016/j.drugalcdep.2004.11.006.
   PubMed Web of Science ®Google Scholar
• Mistler C, Shrestha R, Gunstad J, Sanborn V, Copenhaver M. Adapting behavioral interventions to compensate for cognitive dysfunction in persons with opioid use disorder. General Psychiatry. under review
   Google Scholar
• Sanborn V, Gunstad J, Shrestha R, Mistler CB, Copenhaver MM. Cognitive profiles in persons with opioid use disorder enrolled in methadone treatment. Appl Neuropsychology: Adult. 2020;27:1–7. doi:10.1080/23279095.2020.1769099.
   PubMed Web of Science ®Google Scholar